Representatives across 12 disease groups make up a council that sets clinical recommendations for oncology care and those decisions are being pushed out in the electronic medical record for decision support at the point of care, said Jeffrey Patton, MD, CEO, OneOncology, and executive chairman of the board, Tennessee Oncology. Patton will lead off OneOncology's Physician Leadership Conference, which runs November 11-13 in Nashville.
Representatives across 12 disease groups make up a council that sets clinical recommendations for oncology care and those decisions are being pushed out in the electronic medical record for decision support at the point of care, said Jeffrey Patton, MD, CEO, OneOncology, and executive chairman of the board, Tennessee Oncology. Patton will lead off OneOncology's Physician Leadership Conference, which runs November 11-13 in Nashville.
Transcript
What is the role of disease groups in the OneOncology clinical pathways program? How do member practices of OneOncology work with these clinical pathways day to day?
At OneOncology, we have a clinical leadership forum called One Council—everything's “one” with us. One Council is really a Senate-based model where we have representatives from each practice make clinical decisions and clinical recommendations. Within that group, we have 12 disease groups, where we have thought leaders or folks interested in specific disease discuss and set our standard of care in those disease groups. And then we're developing a pathway to tool with Flatiron Health and called Flatiron Assist, where those recommendations are written into the electronic medical record, so you don't have to go outside of the electronic medical record to get that decision support tool. And it really is decision support at the point of care.
FIT Completion, Yield Rates in CRC Screening Similar After New Screening Guidelines
October 22nd 2024Patients were found to have similar completion and yield rates for the fecal immunochemical test (FIT) at both 45 years and 50 years, making screening for colorectal cancer (CRC) effective in younger patients.
Read More
Delayed Diagnoses, Oxygen Therapy Use Linked to Worse Outcomes in Patients With Fibrotic ILD
October 21st 2024Posters presented at the CHEST 2024 annual meeting revealed that delays in diagnosing fibrotic interstitial lung disease (ILD) can negatively impact overall survival, while supplemental oxygen therapy may exacerbate clinical burdens through increased rates of acute exacerbations and hospitalizations.
Read More
Lower Diagnostic Error Rates Found Among Hospitalized Patients During Care Transitions
October 21st 2024Examining care transitions in hospitalized patients revealed lower diagnostic error rates compared with traditional methods, highlighting the effectiveness of this approach in identifying diagnostic challenges.
Read More